Direct intra-accumbal infusion of a beta-adrenergic receptor antagonist abolishes WIN 55,212-2-induced aversion.
Ana Franky Carvalho, Elisabeth J Van Bockstaele
Index: Neurosci. Lett. 500(1) , 82-5, (2011)
Full Text: HTML
Abstract
The cannabinoid system is known to interact with a variety of neuromodulators in the central nervous system and impacts diverse behaviors. Previous studies have demonstrated that limbic norepinephrine is a critical determinant in the behavioral expression of cannabinoid-induced aversion. The present study was carried out to define the adrenergic receptor subtype involved in mediating cannabinoid-induced behavioral responses. An acute microinjection of the β1-adrenergic receptor blocker, betaxolol, directly into the nucleus accumbens (Acb), was able to prevent WIN 55,212-2-induced aversion, but not lithium-induced aversion, as measured in a place conditioning paradigm. These results suggest that noradrenergic transmission in the Acb is important for cannabinoid-induced aversion and that beta-adrenergic antagonists may be effective in counteracting negative side effects of cannabinoid-based agents.Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.
Related Compounds
Related Articles:
2013-01-01
[Acta Pol. Pharm. 70(4) , 643-52, (2013)]
2012-12-01
[Am. J. Ophthalmol. 154(6) , 958-968.e1, (2012)]
2010-02-15
[Int. J. Pharm. 386(1-2) , 165-71, (2010)]
2011-07-01
[Br. J. Ophthalmol. 95(7) , 966-70, (2011)]
2010-08-01
[Spectrochim. Acta. A. Mol. Biomol. Spectrosc. 76(3-4) , 395-400, (2010)]